AR119902A1 - Proteínas de fusión terapéuticas - Google Patents

Proteínas de fusión terapéuticas

Info

Publication number
AR119902A1
AR119902A1 ARP200102479A ARP200102479A AR119902A1 AR 119902 A1 AR119902 A1 AR 119902A1 AR P200102479 A ARP200102479 A AR P200102479A AR P200102479 A ARP200102479 A AR P200102479A AR 119902 A1 AR119902 A1 AR 119902A1
Authority
AR
Argentina
Prior art keywords
binding domain
injury
inflammatory
fusion protein
integrin
Prior art date
Application number
ARP200102479A
Other languages
English (en)
Inventor
Sebastien Irigaray
Laurent Klein
Darko Skegro
Marco Villani
Karl Welzenbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67875416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR119902(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR119902A1 publication Critical patent/AR119902A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Computer Networks & Wireless Communication (AREA)

Abstract

Reivindicación 1: Una proteína de fusión terapéutica para potenciar la eferocitosis que comprende un dominio de unión a integrina, un dominio de unión a fosfatidilserina (PS) y un dominio de solubilización, donde el dominio de solubilización se inserta entre el dominio de unión a integrina y el dominio de unión a PS; y en donde el dominio de unión a integrina se une a una integrina. Reivindicación 15: Un ácido nucleico aislado que codifica la secuencia de aminoácidos de una cualquiera de las reivindicaciones 11 a 14. Reivindicación 16: Un vector de clonación o expresión que comprende el ácido nucleico de acuerdo con la reivindicación 15. Reivindicación 18: Una composición farmacéutica que comprende la proteína de fusión de una cualquiera de las reivindicaciones 1 a 14 y un portador farmacéuticamente aceptable. Reivindicación 19: La proteína de fusión de una cualquiera de las reivindicaciones 1 a 14 para su uso en el tratamiento o prevención de un trastorno inflamatorio o lesión orgánica inflamatoria en un individuo que lo necesite, en donde el trastorno inflamatorio o lesión orgánica inflamatoria es lesión renal aguda, síndrome de dificultad respiratoria aguda, lesión hepática aguda, sepsis, infarto de miocardio, accidente cerebrovascular, quemaduras, lesión traumática y lesiones inflamatorias y de órganos resultantes de isquemia / reperfusión.
ARP200102479A 2019-09-06 2020-09-04 Proteínas de fusión terapéuticas AR119902A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19196045 2019-09-06

Publications (1)

Publication Number Publication Date
AR119902A1 true AR119902A1 (es) 2022-01-19

Family

ID=67875416

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP200102479A AR119902A1 (es) 2019-09-06 2020-09-04 Proteínas de fusión terapéuticas
ARP200102483A AR119905A1 (es) 2019-09-06 2020-09-04 Proteínas de fusión terapéuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200102483A AR119905A1 (es) 2019-09-06 2020-09-04 Proteínas de fusión terapéuticas

Country Status (22)

Country Link
US (3) US20230308835A1 (es)
EP (3) EP4025238A1 (es)
JP (4) JP7808547B2 (es)
KR (3) KR20220058586A (es)
CN (8) CN119285791A (es)
AR (2) AR119902A1 (es)
AU (3) AU2020343512A1 (es)
BR (2) BR112022003762A2 (es)
CA (3) CA3152500A1 (es)
CO (2) CO2022002567A2 (es)
CR (2) CR20220089A (es)
CU (2) CU20220015A7 (es)
EC (2) ECSP22016180A (es)
IL (3) IL290618A (es)
JO (2) JOP20220058A1 (es)
MX (2) MX2022002638A (es)
MY (1) MY208682A (es)
PE (2) PE20220401A1 (es)
PH (2) PH12022550538A1 (es)
TW (2) TW202122414A (es)
WO (3) WO2021044360A1 (es)
ZA (2) ZA202201827B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113301914B (zh) * 2018-10-25 2026-02-03 尼希尔有限公司 用于治疗和预防纤维化的组合物和方法
EP4326307A4 (en) * 2021-04-22 2025-03-05 Biolegend, Inc. PHOSPHATIDYLSERINE BINDING AGENT FOR THE DETECTION AND DEGRADATION OF PHOSPHATIDYLSERINE-POSITIVE CELLS
KR102801198B1 (ko) * 2021-06-28 2025-04-30 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물
CN114288386B (zh) * 2022-01-25 2023-12-12 华中科技大学同济医学院附属协和医院 Del-1作为炎症性肠病新的生物标志物及治疗药物应用
TW202417520A (zh) * 2022-10-14 2024-05-01 南韓商伊米斯療法股份有限公司 融合分子和治療免疫性疾病的方法
CN119158000B (zh) * 2023-10-25 2025-07-18 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物
WO2025217863A1 (zh) * 2024-04-18 2025-10-23 苏州鲲石一号生物科技有限公司 Gas6融合蛋白及其制备方法与应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
AU2006243905B2 (en) 2005-05-13 2011-09-01 The Feinstein Institute For Medical Research Milk fat globule epidermal growth factor-factor VIII and sepsis
CN101511866A (zh) * 2006-09-08 2009-08-19 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2215264B1 (en) * 2007-11-15 2015-04-01 The Feinstein Institute for Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
AU2010311332B2 (en) 2009-10-30 2015-04-23 Albumedix Ltd. Albumin variants
WO2011103076A1 (en) 2010-02-16 2011-08-25 Medlmmune, Llc Hsa-related compositions and methods of use
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
WO2012059486A1 (en) 2010-11-01 2012-05-10 Novozymes Biopharma Dk A/S Albumin variants
WO2012106615A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
EP2675471A4 (en) 2011-02-15 2015-01-28 Medimmune Llc HSA-RELATED COMPOSITIONS AND USE PROCESSES
AU2012249539A1 (en) * 2011-04-28 2013-11-14 The Feinstein Institute For Medical Research MFG-E8 and uses thereof
WO2012150319A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
AU2014217831A1 (en) 2013-02-16 2015-07-16 Albumedix Ltd. Pharmacokinetic animal model
EP3037534B1 (en) 2013-08-23 2021-02-17 Riken Polypeptide exhibiting fluorescent properties, and utilization of same
KR102385120B1 (ko) * 2014-03-31 2022-04-12 한미약품 주식회사 면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
WO2015150757A1 (en) * 2014-03-31 2015-10-08 British Telecommunications Public Limited Company Data communication
US20170136089A1 (en) * 2014-05-15 2017-05-18 The Trustees Of The University Of Pennsylvania Compositions and methods of regulating bone resorption
KR20170013621A (ko) 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
CA3000742A1 (en) 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
EP3589650A1 (en) * 2017-03-02 2020-01-08 Novartis AG Engineered heterodimeric proteins
KR101947902B1 (ko) 2017-05-17 2019-02-13 (주) 넥셀 간 섬유화 예방 또는 치료용 재조합 단백질 및 이를 포함하는 간 섬유화 예방 또는 치료용 조성물
CN113301914B (zh) 2018-10-25 2026-02-03 尼希尔有限公司 用于治疗和预防纤维化的组合物和方法

Also Published As

Publication number Publication date
CA3152500A1 (en) 2021-03-11
CO2022002545A2 (es) 2022-04-08
MX2022002638A (es) 2022-03-25
ZA202201827B (en) 2023-11-29
ZA202201828B (en) 2023-10-25
JP7671739B2 (ja) 2025-05-02
CN119285791A (zh) 2025-01-10
MY208682A (en) 2025-05-23
JOP20220058A1 (ar) 2023-01-30
US20230265160A1 (en) 2023-08-24
JP7808547B2 (ja) 2026-01-29
JP2025124629A (ja) 2025-08-26
JP7834637B2 (ja) 2026-03-24
EP4025238A1 (en) 2022-07-13
KR20220058586A (ko) 2022-05-09
EP4025239A1 (en) 2022-07-13
US20230220048A1 (en) 2023-07-13
US20230308835A1 (en) 2023-09-28
KR20220058585A (ko) 2022-05-09
KR20220058588A (ko) 2022-05-09
CA3152990A1 (en) 2021-03-11
IL290618A (en) 2022-04-01
PH12022550538A1 (en) 2023-03-20
AR119905A1 (es) 2022-01-19
CU20220015A7 (es) 2022-10-11
PE20220401A1 (es) 2022-03-22
PH12022550539A1 (en) 2023-03-20
CN118812727A (zh) 2024-10-22
WO2021044362A1 (en) 2021-03-11
AU2020343926A1 (en) 2022-04-07
WO2021044361A1 (en) 2021-03-11
JOP20220055A1 (ar) 2022-03-02
CN114341195A (zh) 2022-04-12
WO2021044360A1 (en) 2021-03-11
AU2020343926B2 (en) 2024-11-21
CR20220096A (es) 2022-05-11
AU2020340618A1 (en) 2022-04-07
CN114341195B (zh) 2025-04-25
TW202122415A (zh) 2021-06-16
IL290675A (en) 2022-04-01
CN118667031A (zh) 2024-09-20
MX2022002637A (es) 2022-03-25
CO2022002567A2 (es) 2022-04-08
CN118772293A (zh) 2024-10-15
PE20221051A1 (es) 2022-06-30
CA3152499A1 (en) 2021-03-11
CR20220089A (es) 2022-03-30
CN114341194A (zh) 2022-04-12
IL290660A (en) 2022-04-01
JP2022547050A (ja) 2022-11-10
EP4025237A1 (en) 2022-07-13
ECSP22016180A (es) 2022-04-29
ECSP22016558A (es) 2022-04-29
JP2022547111A (ja) 2022-11-10
JP2022547051A (ja) 2022-11-10
TW202122414A (zh) 2021-06-16
TWI873177B (zh) 2025-02-21
BR112022003745A2 (pt) 2022-05-31
AU2020340618B2 (en) 2025-01-23
BR112022003762A2 (pt) 2022-05-31
AU2020343512A1 (en) 2022-04-07
CN118909136A (zh) 2024-11-08
CN114302896A (zh) 2022-04-08
CU20220016A7 (es) 2022-10-11

Similar Documents

Publication Publication Date Title
AR119905A1 (es) Proteínas de fusión terapéuticas
MX2024014691A (es) Enlazadores de conjugacion mejorados
AR119080A1 (es) Proteínas multiespecíficas
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
AR080914A1 (es) Proteinas de union al beta-amiloide
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
Dekan et al. Total synthesis of human hepcidin through regioselective disulfide‐bond formation by using the safety‐catch cysteine protecting group 4, 4′‐dimethylsulfinylbenzhydryl
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
MX2015000397A (es) Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos.
CL2025001961A1 (es) Compuestos y métodos para el tratamiento de infecciones virales
AR074399A1 (es) Moleculas biespecificas de union a egfr/igfir
AR050353A1 (es) Composicion de anticuerpo her2
AR038568A1 (es) Anticuerpos anti-a beta y su uso
DOP2023000037A (es) Compuestos fosfolípidos y usos de los mismos
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
BR112018073669A2 (pt) proteína de fusão, composição de uma primeira proteína e uma segunda proteína, complexo de uma primeira proteína e uma segunda proteína, polinucleotídeos que codificam uma proteína de fusão, vetor contendo o polinucleotídeo, célula hospedeira contendo o polinucleotídeo, uso de uma proteína de fusão, composição farmacêutica, e composição farmacêutica para uso
CL2020003292A1 (es) Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969)
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
AR066311A1 (es) Moleculas de anticuerpos anti proteina hsp90 fungica y acidos nucleicos que los codifican
MX2023011645A (es) Materiales y métodos para la redirección de células efectoras inmunitarias.
DOP2024000172A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
DOP2024000171A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
CO2026002249A2 (es) Compuestos antivirales y métodos de elaboración y uso de los mismos